Anti-Rheumatic Drugs - Sudan

Sudan

In Sudan, the revenue in the Anti-Rheumatic Drugs market is forecasted to reach US$1.50m in 2024.
The market is expected to witness a steady annual growth rate (CAGR 2024-2029) of -1.09%, which will result in a market volume of US$1.42m by 2029.
When compared globally, United States is projected to generate the highest revenue of US$34,700.00m in 2024.
The demand for anti-rheumatic drugs in Sudan is increasing due to the high prevalence of rheumatic diseases in the country.

Key regions: Germany, United States, India, Japan, United Kingdom

Market

Region

Region comparison

Currency

Analyst Opinion

The Anti-Rheumatic Drugs market in Sudan has been steadily growing in recent years.

Customer preferences: Customers in Sudan have shown a growing demand for Anti-Rheumatic Drugs due to an increase in the prevalence of rheumatic diseases. Rheumatoid arthritis, in particular, has been on the rise in Sudan, leading to an increase in demand for drugs that can alleviate symptoms and improve quality of life.

Trends in the market: The Anti-Rheumatic Drugs market in Sudan has been growing at a steady pace due to the increasing prevalence of rheumatic diseases in the country. This trend is expected to continue in the coming years as the population ages and the incidence of rheumatic diseases continues to rise. Additionally, as the healthcare system in Sudan continues to improve, more patients are seeking treatment for their conditions, further driving demand for Anti-Rheumatic Drugs.

Local special circumstances: Sudan faces several unique challenges in the Anti-Rheumatic Drugs market. The country has a relatively small population, which can limit the market size for certain drugs. Additionally, the healthcare system in Sudan is still developing, which can make it difficult for patients to access the care and medication they need. However, the government has taken steps to improve the healthcare system, which could help to address some of these challenges in the coming years.

Underlying macroeconomic factors: Sudan's economy has been impacted by political instability and economic sanctions in recent years, which has made it difficult for the healthcare system to keep up with rising demand for drugs and services. However, the government has taken steps to address these issues, including lifting some economic sanctions and investing in healthcare infrastructure. These efforts could help to support continued growth in the Anti-Rheumatic Drugs market in Sudan.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.